Published in Proc Natl Acad Sci U S A on September 30, 1997
Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics (2004) 2.49
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09
Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics (2007) 2.05
Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J (2002) 1.68
The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J (2000) 1.62
Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J Exp Med (2000) 1.59
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest (2009) 1.54
Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A (2004) 1.51
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics (2010) 1.37
Immunoinformatics comes of age. PLoS Comput Biol (2006) 1.35
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol (2009) 1.30
EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics (2006) 1.26
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
Integrated modeling of the major events in the MHC class I antigen processing pathway. Protein Sci (2005) 1.23
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22
Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol (2005) 1.21
Proteases in MHC class I presentation and cross-presentation. J Immunol (2010) 1.15
PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res (2005) 1.14
Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med (1999) 1.14
Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J (1999) 1.13
Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences. Nucleic Acids Res (2005) 1.11
An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort. J Virol (2007) 1.10
Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci U S A (1998) 1.07
The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol (2011) 1.04
Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol (2010) 1.02
ER stress affects processing of MHC class I-associated peptides. BMC Immunol (2009) 1.02
Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med (2000) 1.01
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J Exp Med (2002) 1.00
Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun (2005) 0.99
Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J Exp Med (1998) 0.98
Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol (2006) 0.98
Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo. J Immunol (2009) 0.97
Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. BMC Bioinformatics (2010) 0.94
Hepatitis C virus and ethanol alter antigen presentation in liver cells. World J Gastroenterol (2009) 0.94
Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. J Exp Med (2002) 0.91
The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem (2009) 0.90
Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood (2006) 0.87
The immunoproteasome and viral infection: a complex regulator of inflammation. Front Microbiol (2015) 0.86
Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway. Infect Immun (2002) 0.86
The distribution of CTL epitopes in HIV-1 appears to be random, and similar to that of other proteomes. BMC Evol Biol (2009) 0.86
The specificity and polymorphism of the MHC class I prevents the global adaptation of HIV-1 to the monomorphic proteasome and TAP. PLoS One (2008) 0.85
PolyCTLDesigner: a computational tool for constructing polyepitope T-cell antigens. BMC Res Notes (2013) 0.83
The amino acid sequences flanking an antigenic determinant can strongly affect MHC class I cross-presentation without altering direct presentation. J Immunol (2009) 0.83
PA28αβ: the enigmatic magic ring of the proteasome? Biomolecules (2014) 0.81
The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Sci Rep (2015) 0.80
Peptide crosslinked micelles: a new strategy for the design and synthesis of peptide vaccines. Int J Nanomedicine (2006) 0.80
Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules (2014) 0.79
Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant. PLoS One (2013) 0.78
Glucagon-reactive islet-infiltrating CD8 T cells in NOD mice. Immunology (2015) 0.78
Characterizing the specificity and cooperation of aminopeptidases in the cytosol and endoplasmic reticulum during MHC class I antigen presentation. J Immunol (2010) 0.78
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother (2011) 0.78
T-cell recognition is shaped by epitope sequence conservation in the host proteome and microbiome. Immunology (2016) 0.78
Mechanism of antigen presentation after hypertonic loading of soluble antigens. Immunology (2002) 0.77
An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects. J Immunol (2012) 0.77
Effects of changes in food supply at the time of sex differentiation on the gonadal transcriptome of juvenile fish. Implications for natural and farmed populations. PLoS One (2014) 0.75
Infection with Salmonella typhimurium has no effect on the composition and cleavage specificity of the 20S proteasome in human lymphoid cells. Immunology (2007) 0.75
Proteasomal cleavage site prediction of protein antigen using BP neural network based on a new set of amino acid descriptor. J Mol Model (2013) 0.75
The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature (1987) 12.43
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem (1996) 10.70
The ubiquitin-proteasome proteolytic pathway. Cell (1994) 9.75
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature (1991) 3.84
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (1993) 3.65
Antigen presentation by Ia+ B cell hybridomas to H-2-restricted T cell hybridomas. Proc Natl Acad Sci U S A (1982) 3.41
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
MHC class I expression in mice lacking the proteasome subunit LMP-7. Science (1994) 3.17
Proteolysis, proteasomes and antigen presentation. Nature (1992) 3.15
Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science (1993) 3.06
Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol (1996) 2.69
Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem (1992) 2.48
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem (1997) 2.39
Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity (1994) 2.39
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Degradation of proteins within the endoplasmic reticulum. Curr Opin Cell Biol (1991) 2.22
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (1993) 2.11
Proteasomes: multicatalytic proteinase complexes. Biochem J (1993) 2.08
Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell (1992) 1.93
Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. J Immunol (1994) 1.85
Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med (1991) 1.77
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Proteolysis. The proteasome: a protein-degrading organelle? Curr Biol (1995) 1.74
The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem (1995) 1.70
Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity (1995) 1.59
Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science (1994) 1.58
Generation of class I MHC-restricted T-T hybridomas. J Immunol (1990) 1.55
Trimming of antigenic peptides in an early secretory compartment. J Exp Med (1994) 1.47
Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity (1994) 1.46
The LMP antigens: a stable MHC-controlled multisubunit protein complex. Hum Immunol (1986) 1.28
The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. Immunity (1996) 1.04
Regulation of class I-restricted epitope processing by local or distal flanking sequence. J Immunol (1997) 1.01
The role of MHC class I molecules in the generation of endogenous peptide/MHC complexes. J Immunol (1995) 0.99
Induction of leucine aminopeptidase by interferon-gamma. Identification by protein microsequencing after purification by preparative two-dimensional gel electrophoresis. J Biol Chem (1992) 0.89
Functions of the proteasome in antigen presentation. Cold Spring Harb Symp Quant Biol (1995) 0.89
The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen. J Exp Med (1996) 0.86
Role for MHC class I molecules in selecting and protecting high affinity peptides in the presence of proteases. J Immunol (1994) 0.80
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol (1997) 5.06
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. J Bone Joint Surg Br (2003) 4.16
Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (1999) 4.13
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (1993) 3.65
Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med (1984) 3.36
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
Proteolysis, proteasomes and antigen presentation. Nature (1992) 3.15
Blood-lead and hypertension. Lancet (1976) 2.82
Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol (1996) 2.69
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem (1997) 2.39
Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity (1994) 2.39
Environmental lead pollution in an urban soft-water area. Br Med J (1972) 2.28
The diagnosis of industrial lead poisoning. Br J Ind Med (1968) 2.23
A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (1993) 2.11
Do pregnant women take their iron? Lancet (1969) 2.10
Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A (2000) 2.10
26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J (2001) 2.09
Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci U S A (1994) 2.08
Lead poisoning in rural Scotland. Br Med J (1972) 2.08
Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med (1995) 2.06
Summaries and selective destruction as a solution to the hospital record storage problem. Lancet (1967) 2.05
Choleic acids. Biochem J (1932) 2.02
Lead and delta-aminolaevulinic acid dehydratase levels in mentally retarded children and in lead-poisoned suckling rats. Lancet (1970) 1.93
Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers. Evidence of specific competition for accessory cell antigen presentation. J Exp Med (1983) 1.92
Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med (1977) 1.91
Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. Aliment Pharmacol Ther (2012) 1.89
P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol (2001) 1.86
Diagnosis of upper gastro-intestinal bleeding. Br Med J (1965) 1.84
Structural characterization of the TAP molecule: a phosphatidylinositol-linked glycoprotein distinct from the T cell receptor/T3 complex and Thy-1. Cell (1986) 1.77
Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant (2013) 1.77
Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A (1996) 1.76
Controlled trial of haem arginate in acute hepatic porphyria. Lancet (1989) 1.75
Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. J Immunol (1985) 1.64
Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem (1998) 1.60
Skin test results and self-reported symptom severity in allergic rhinitis: The role of psychological factors. Clin Exp Allergy (2006) 1.59
The drug disc. Warning system for drug interactions. Lancet (1973) 1.56
An assessment of digoxin radio-immunoassay. Scott Med J (1973) 1.55
Unified nomenclature for subunits of the Saccharomyces cerevisiae proteasome regulatory particle. Trends Biochem Sci (1998) 1.55
Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy. Clin Exp Allergy (1999) 1.52
TAP, a novel T cell-activating protein involved in the stimulation of MHC-restricted T lymphocytes. J Exp Med (1986) 1.49
Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev (1999) 1.47
Magnesium binding by Escherichia coli ribosomes. J Mol Biol (1966) 1.46
Depression of delta-aminolaevulic acid dehydrase activity by ethanol in man and rat. Clin Sci (1971) 1.45
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology (1996) 1.45
Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol (2001) 1.41
Blood lead levels in normal and mentally deficiency children. Arch Dis Child (1967) 1.41
Ascorbic-acid levels in leucocytes of patients with gastrointestinal haemorrhage. Lancet (1968) 1.40
Writing case histories. Int J Psychoanal (1997) 1.39
Between empathy and judgment. J Am Psychoanal Assoc (1999) 1.38
Medics in the Israel Defense Forces and their experience in trauma care during peacetime. Isr Med Assoc J (1999) 1.38
Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation (1995) 1.36
TAP transcription and phosphatidylinositol linkage mutants are defective in activation through the T cell receptor. Cell (1988) 1.36
Acute intermittent porphyria: response of tachycardia and hypertension to propranolol. Br Med J (1973) 1.35
Treatment with haematin in acute hepatic porphyria. Q J Med (1981) 1.29
Renal insufficiency associated with excessive lead exposure. Br Med J (1977) 1.29
Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology (2004) 1.29
Strength training increases resting metabolic rate and norepinephrine levels in healthy 50- to 65-yr-old men. J Appl Physiol (1985) (1994) 1.29
Stimulation of B lymphocytes through surface Ig receptors induces LFA-1 and ICAM-1-dependent adhesion. J Immunol (1991) 1.27
Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J Biol Chem (1996) 1.27
Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J Biol Chem (2001) 1.26
Selective modification of a private I-A allo-stimulating determinant(s) upon association of antigen with an antigen-presenting cell. J Exp Med (1984) 1.25
Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol (1996) 1.24
Role of ICAM-1 in antigen presentation demonstrated by ICAM-1 defective mutants. J Immunol (1990) 1.24
Fully mobilizing host defense: building better vaccines. Nat Biotechnol (1998) 1.23
Lead poisoning as a disorder of heme synthesis. Semin Hematol (1968) 1.22
Cloning and expression of a cDNA for the T-cell-activating protein TAP. Proc Natl Acad Sci U S A (1988) 1.21
Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol (1995) 1.20
Drinking water as a source of lead pollution. Environ Health Perspect (1974) 1.19
MHC-restricted T cell activation: analysis with T cell hybridomas. Immunol Rev (1983) 1.19
Induction of delta-aminolaevulinic acid synthase in leucocytes of patients on phenytoin therapy--comparison with changes in rat hepatic tissue. Br J Clin Pharmacol (1980) 1.19
Tetraethyl-lead poisoning. Lancet (1972) 1.18
Screening for latent acute intermittent porphyria: the value of measuring both leucocyte delta-aminolaevulinic acid synthase and erythrocyte uroporphyrinogen-1-synthase activities. J Med Genet (1982) 1.15
[Contribution of lead in drinking water to blood-lead]. Lancet (1977) 1.15
Stimulation of T cells via the TAP molecule, a member in a family of activating proteins encoded in the Ly-6 locus. J Immunol (1987) 1.14
Overexpressed Ly-6A.2 mediates cell-cell adhesion by binding a ligand expressed on lymphoid cells. Proc Natl Acad Sci U S A (1995) 1.12
Measurement of leucocyte ascorbic acid. Br Med J (1966) 1.12
Internalization of glycosyl-phosphatidylinositol (GPI)-anchored lymphocyte proteins. II. GPI-anchored and transmembrane molecules internalize through distinct pathways. Eur J Immunol (1992) 1.12
Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J Immunol (2000) 1.12
Lead poisoning and haem biosynthesis. Br J Haematol (1972) 1.11
Hereditary coproporphyria. Lancet (1967) 1.11
Blood-lead and cadmium in human hypertension. J Environ Pathol Toxicol (1980) 1.09
MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol (1992) 1.09
Heterogeneity in antigen processing by different types of antigen-presenting cells. Effect of cell culture on antigen processing ability. J Immunol (1992) 1.09
The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J Immunol (1998) 1.09
Autonomic neuropathy in acute intermittent porphyria. J Neurol Neurosurg Psychiatry (1985) 1.07
Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc Natl Acad Sci U S A (1998) 1.07
T cell receptor/CD3 negative variants are unresponsive to stimulation through the Ly-6 encoded molecule, TAP. J Immunol (1988) 1.06
Rapid degradation of an abnormal protein in Escherichia coli proceeds through repeated cycles of association with GroEL. J Biol Chem (1999) 1.05
mu-opioid receptors are present in vagal afferents and their dendritic targets in the medial nucleus tractus solitarius. J Comp Neurol (2000) 1.05
Refractory anemia with dysproteinemia: long-term therapy with low-dose corticosteroids. Blood (1973) 1.05
The role of Ia molecules in the activation of T lymphocytes. II. Ia-restricted recognition of allo K/D antigens is required for class I MHC-stimulated mixed lymphocyte responses. J Immunol (1983) 1.05
Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers. II. Competitive inhibition of I-E-restricted, antigen-specific T cell responses. J Exp Med (1984) 1.05
The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J Immunol (1991) 1.05
The effect of calcium on lead absorption in rats. Biochem J (1977) 1.05